The director of the Melanoma Program at Cedars-Sinai Medical Center discussed evaluation criteria for TIL therapy in melanoma.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Omid Hamid, MD, director, Melanoma Program, Cedars-Sinai Medical Center, chief, Translational Research and Immunotherapy, and director, Melanoma Therapeutics, Phase I Immuno-Oncology Program, The Angeles Clinic and Research Institute, to learn more about the differences in evaluation criteria for tumor-infiltrating lymphocytes (TIL) therapy in melanoma.
The use of adoptive T-cell therapy in melanoma is still new and there is still more to be learned in the field. Immunotherapy is being evaluated with immune RECIST criteria, allowing for some initial progression until the immune system takes effect. The ability to evaluate trials against one another is difficult, as the cohorts are heterogeneous and prior therapies patients received are not similar, Hamid explained. However, trials have opened examining patients with melanoma who received TIL therapy during a period of stable disease with PD-1 inhibitors.
Moreover, cohorts are opening with patients who've developed toxicity with prior checkpoint inhibitors, Hamid continues. Trials are evaluating whether the preconditioning regimens can be changed, whether TIL therapy administration can be changed, and whether other therapies can replace high-dose IL-2, Hamid explains. As such, the field is evaluating the convergence of newer treatments to augment adoptive T-cell therapy, Hamid concludes.